TheraRadar

Competitive Landscape by Indication

Data updated: Sep 20, 2026

158 indications, 118,652 trials mapped

Oncology

55,867 trials
Solid Tumor (Advanced)
9695 trials 895 Ph3
Merck, Sichuan Baili Pharmaceutical Co., Ltd., GSK
Breast Cancer
4015 trials 720 Ph3
AstraZeneca, Roche, Pfizer
Non-Hodgkin Lymphoma
3968 trials 358 Ph3
Roche, Merck, Genmab
NSCLC
3472 trials 565 Ph3
AstraZeneca, Merck, Sichuan Baili Pharmaceutical Co., Ltd.
Colorectal Cancer
2647 trials 373 Ph3
AbbVie, AstraZeneca, Revolution Medicines, Inc.
Prostate Cancer
2328 trials 357 Ph3
Novartis, AstraZeneca, Jiangsu HengRui Medicine Co., Ltd.
Multiple Myeloma
1958 trials 238 Ph3
Johnson & Johnson, GSK, AbbVie
AML
1842 trials 177 Ph3
AbbVie, Taiho Oncology, Inc., Kura Oncology, Inc.
Hematologic Malignancies
1737 trials 152 Ph3
Johnson & Johnson, Novartis, Merck
Melanoma
1676 trials 142 Ph3
Bristol-Myers Squibb, Merck, Regeneron
Pancreatic Cancer
1619 trials 141 Ph3
Revolution Medicines, Inc., Astellas, AstraZeneca
Hepatocellular Carcinoma
1442 trials 221 Ph3
AstraZeneca, Akeso, Roche
Ovarian Cancer
1413 trials 169 Ph3
AstraZeneca, AbbVie, Merck
Lung Cancer (General)
1331 trials 171 Ph3
Chongqing Precision Biotech Co., Ltd, AstraZeneca, Avistone Biotechnology Co., Ltd.
Head and Neck Cancer
1265 trials 116 Ph3
Sichuan Baili Pharmaceutical Co., Ltd., AstraZeneca, Rakuten Medical, Inc.
MDS
1200 trials 99 Ph3
Bristol-Myers Squibb, Takeda, Taiho Oncology, Inc.
Gastric Cancer
1118 trials 186 Ph3
AstraZeneca, Astellas, Chongqing Precision Biotech Co., Ltd
Sarcoma
1061 trials 74 Ph3
USWM CT, LLC, Hansoh BioMedical R&D Company, Eli Lilly
Bladder Cancer
1003 trials 141 Ph3
Merck, AstraZeneca, Pfizer
Glioblastoma
988 trials 65 Ph3
Novartis, GT Medical Technologies, Inc., Philogen S.p.A.
ALL
947 trials 93 Ph3
Novartis, Amgen, Chongqing Precision Biotech Co., Ltd
Esophageal Cancer
818 trials 134 Ph3
AstraZeneca, Merck, Sichuan Baili Pharmaceutical Co., Ltd.
Brain Tumor
805 trials 57 Ph3
Pfizer, Nuvation Bio Inc., InSightec
Renal Cell Carcinoma
788 trials 72 Ph3
Merck, Exelixis, Bristol-Myers Squibb
CLL
785 trials 83 Ph3
BeOne Medicines, Acerta Pharma BV, AbbVie
Squamous Cell Carcinoma
664 trials 65 Ph3
Regeneron, Merck, AstraZeneca
Triple Negative Breast Cancer
611 trials 70 Ph3
Gilead, Novartis, AstraZeneca
Cholangiocarcinoma
606 trials 63 Ph3
AstraZeneca, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Eli Lilly
SCLC
571 trials 76 Ph3
Amgen, Boehringer Ingelheim, Merck
Cervical Cancer
535 trials 90 Ph3
AstraZeneca, Merck, Shanghai Bovax Biotechnology Co., Ltd.
Hodgkin Lymphoma
484 trials 36 Ph3
Merck, Takeda, Tessa Therapeutics
Endometrial Cancer
468 trials 48 Ph3
AstraZeneca, Merck, Genmab
CML
403 trials 44 Ph3
Novartis, Shenzhen TargetRx Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd.
Neuroendocrine Tumors
328 trials 42 Ph3
Advanced Accelerator Applications, Crinetics Pharmaceuticals Inc., Merck
Myelofibrosis
286 trials 35 Ph3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis, Bristol-Myers Squibb
Mesothelioma
282 trials 18 Ph3
Novartis, AstraZeneca, Vivace Therapeutics, Inc
Thyroid Cancer
233 trials 35 Ph3
Exelixis, Eli Lilly, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HER2+ Breast Cancer
193 trials 34 Ph3
Sichuan Baili Pharmaceutical Co., Ltd., Roche, Jazz Pharmaceuticals
HER2- Breast Cancer
180 trials 20 Ph3
AstraZeneca, Novartis, BeOne Medicines
Merkel Cell Carcinoma
102 trials 6 Ph3
TuHURA Biosciences, Inc., ImmunityBio, Inc., Novartis

CNS

10,571 trials
Major Depression
1790 trials 483 Ph3
Neurocrine Biosciences, Johnson & Johnson, Cybin IRL Limited
Alzheimer's Disease
1547 trials 296 Ph3
Eli Lilly, Bristol-Myers Squibb, Roche
Schizophrenia
955 trials 257 Ph3
Neurocrine Biosciences, Luye Pharma Group Ltd., Bristol-Myers Squibb
Parkinson's Disease
943 trials 176 Ph3
iRegene Therapeutics Co., Ltd., Roche, Luye Pharma Group Ltd.
Multiple Sclerosis
874 trials 236 Ph3
Roche, Novartis, Sanofi
Migraine
523 trials 199 Ph3
Pfizer, AbbVie, H. Lundbeck A/S
Epilepsy
470 trials 171 Ph3
Praxis Precision Medicines, Biohaven Therapeutics Ltd., Rapport Therapeutics Inc.
Anxiety
468 trials 109 Ph3
Otsuka Pharmaceutical Development & Commercialization, Inc., VistaGen Therapeutics, Inc., Beijing Union Pharmaceutical Factory Ltd
Alcohol Use Disorder
450 trials 72 Ph3
Eli Lilly, Pop Test Oncology LLC, Newleos Therapeutics, Inc.
Opioid Use Disorder
430 trials 91 Ph3
Go Medical Industries Pty Ltd, Akyso Therapeutics, LLC, Eli Lilly
ALS
353 trials 72 Ph3
Eli Lilly, Biogen, Amylyx Pharmaceuticals Inc.
ADHD
341 trials 122 Ph3
Otsuka Pharmaceutical Co., Ltd., Axsome Therapeutics, Inc., Bazelet Nehushtan LtD.
Autism Spectrum Disorder
340 trials 65 Ph3
Intra-Cellular Therapies, Inc., Bristol-Myers Squibb, Curemark
PTSD
321 trials 65 Ph3
Oui Therapeutics, Inc., COMPASS Pathways, Senseye, Inc.
Bipolar Disorder
292 trials 96 Ph3
Bristol-Myers Squibb, Intra-Cellular Therapies, Inc., Xenon Pharmaceuticals Inc.
Neuropathy
284 trials 70 Ph3
argenx, WinSanTor, Inc, Rinri Therapeutics
Huntington's Disease
106 trials 18 Ph3
Roche, Skyhawk Therapeutics, Inc., Novartis
OCD
84 trials 11 Ph3
Vericel Corporation, Biohaven Pharmaceuticals, Inc., Roche

Click any indication to see full competitive landscape (all sponsors, trials, phases).

Data: ClinicalTrials.gov | Mapping: Indication Taxonomy